Top line efficacy certainly on par. Will be interesting to see tolerability. My guess is that falls somewhere between PFE (low reactogenicity) and GSK. Corresponding efficacy may also fall between PFE (lowest) and GSK although tough to call because numbers are small so far GSK and PFE are going to have 2 year durability data mid year. MRNA is probably looking at launch in 2024-25 RSV season and by then JNJ may be a player as well. We will learn about durability of mRNA relative to other platforms next year as I assume FDA asked MRNA to follow some vaccine patients for up to 3 years as well.
I found this summary of the older adult rsv vaccine landscape. It's a quick comparison of top line data that we have to date, and the other players who are expecting data soon. It's superficial and omits some important details (and obviously a lot of data is still not public), but still a nice succinct overview of where things stand today
Market Data 
Markets 
AI
